Vigabatrin Oral Solution
Category: Neurology
FDA status: To Be Discontinued · Last FDA update: Oct 16, 2025 · First posted: Oct 16, 2025 · 1 manufacturers, 1 listed presentations
As of Oct 16, 2025, the FDA lists Vigabatrin Oral Solution as being discontinued. Of 1 manufacturer presentations, 1 Not specified.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Vigpoder, Oral Solution, 50 mg/1 mL (NDC 80789-117-50) NDC 80789-117-50 |
Pyros Pharmaceuticals, Inc. | Not specified | Discontinuation of the manufacture of the drug |
Related medications in shortage
Other Neurology medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Vigabatrin Oral Solution (FDA data as of Oct 16, 2025). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Vigabatrin Oral Solution. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/vigabatrin-oral-solution.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).